Dr. Joseph Tucker discusses the potential of psychedelic-derived medicines - Calgary - Canada's Podcast

<p>Dr. Joseph Tucker is President and CEO of <a href='https://www.magicmedindustries.com'>MagicMed Industries Inc.</a>, a biotechnology company founded in 2020. The company is focused on creating a library of novel derivative molecules based on classic psychedelics such as psilocybin, N,N-dimethyltryptamine (DMT), mescaline, ibogaine, MDMA and LSD. MagicMed’s molecular derivatives library, the Psybrary™️, is intended to be an essential building block from which industry partners can develop new patented products. MagicMed’s mission is to unlock the full potential of psychedelic-derived medicines. The company is focused on the discovery and development of novel drug candidates, structurally related to classic psychedelics but with improved pharmaceutical characteristics.</p> <p>Entrepreneurs are the backbone of Canada’s economy. To support Canada’s businesses, subscribe to our <a href='https://www.youtube.com/canadaspodcast'>YouTube</a> channel and follow us on <a href='https://www.facebook.com/canadaspodcast/'>Facebook</a>, <a href='http://instagram.com/canadaspodcast'>Instagram</a>, <a href='https://www.linkedin.com/company/canadas-podcast/'>LinkedIn</a> and <a href='https://twitter.com/canadaspodcast'>Twitter</a>.</p> <p>Want to stay up-to-date on the latest #entrepreneur podcasts and news? <a href='https://canadaspodcast.com/newsletter-signup'>Subscribe</a> to our bi-weekly newsletter</p>